Genenta Science SPA (GNTA)

GNTA.....................p/m

Genenta Science evaluates biotech partnerships as it shifts strategic focusMarch 24, 2026 6:41 AM
IH Market News
Genenta Science S.p.A. (NASDAQ:GNTA) said it is continuing to work with DC Advisory to assess potential collaboration opportunities for its biotechnology platform, which stems from research conducted by founder-scientists Professor Luigi Naldini and Bernhard Gentner. The company noted that DC Advisory has not identified any strategic partners to date and that Genenta is not currently engaged in discussions concerning either its Temferon therapy or its broader biotechnology platform.The Milan-based firm is undergoing a strategic transformation into Saentra Forge, subject to shareholder approval. Under the new structure, the company aims to act as an industrial consolidator targeting sectors such as biotechnology, defense, aerospace and technologies tied to national security. Chief Executive Officer Pierluigi Paracchi said the strategy will focus on identifying promising scale-up companies in areas relevant to national security and supporting them with capital, operational structure and access to U.S. public markets through Genenta’s Nasdaq listing.Paracchi also stated that he has retained all of his shares and has increased his stake by purchasing American Depositary Shares during permitted trading periods. He added that the company opposes any sale of shares by the founder-scientists unless Temferon obtains significant third-party validation.The planned transformation marks a major shift from Genenta’s original focus on biotechnology development. The company said it will continue exploring partnership opportunities for its biotech platform based on the scientific research and early clinical data generated to date.Genenta described its revised strategy as the creation of an industrial aggregation platform operating in strategically sensitive industries including cybersecurity, defense, aerospace and biotechnology, according to a company press release.Genenta Science stock price

Original: Genenta Science evaluates biotech partnerships as it shifts strategic focus

GNTA.........................................https://stockcharts.com/sc3/ui/?s=GNTA&p=w&b=5&g=0&id=p86431144783

$12.17.. Genenta Science S.p.A. (GNTA) reported a net loss of approximately $9.23 million in its most recent quarter, according to the latest available income statement data. This confirms the company's continued lack of profitability in its recent financial performance

Nice one will be back down.. Amemocyte itself does not appear to be directly generating significant revenue or profit. Its partner, Humacyte, has launched products and reported some revenue, but the revenue figures are modest and the company still incurs operating losses due to ongoing costs in development and commercialization. For example, Humacyte's total revenue for Q1 2025 was $517,000, with operating expenses much higher, resulting in a loss from operations of about $23.18 million...

$GNTA: End of Week FLIER........ now $13............

Actually tapped $44............ WOW.

Nice nice moveeeeeeeeeeeee


GO $GNTA

GNTA under $6

GNTA under $5

GNTA under $6

What leaked

GNTA under $3

FDA’s decision to grant Orphan Drug Designation to Temferon









glta

$GNTA: Just got a $15 PriceTarget upgrade.

From here $5, looks like its gonna be a nice ride up


GO $GNTA

Maxim starts Genenta Science at buy; PT $21

Stephen Kilmer

January 13, 2022

Maxim Group launched coverage of Genenta Science S.p.A (NASDAQ:GNTA) with a “buy” rating and $21 price target. The stock closed at $9.94 on Jan. 12.

Genenta is developing cancer therapeutics using an autologous ex-vivo, lentiviral-based gene therapy strategy.

The company initially is targeting unmethylated-MGMT glioblastoma multiforme (GBM) patients with its lead gene therapy, Temferon, which is currently being evaluated in a Phase 1/2 dose-escalation study. Data from the latter two cohorts are expected around the end of 2022.

“Tumor agnostic gene therapy, Temferon, can potentially be applied broadly to multiple cancer types because it is not tumor dependent,” writes analyst Naureen Quibria, Ph.D.

She said lentiviral-based gene therapy is a validated approach, with treatment approvals seen in Kymriah for acute lymphoblastic leukemia and diffuse large B-cell lymphoma, Zynteglo for ß-thalassemia, and Libmeldy for metachromatic leukodystrophy.

Genenta’s Temferon, has also demonstrated initial signals of efficacy in its Phase 1/2 clinical study in GBM, as well as robust activity in multiple tumor models in preclinical studies.

“Though the program is somewhat early, we believe the broad utility of the platform and potential durability of the approach support a ‘buy’ rating and our $21 price target,” Dr. Quibria said.

is this genta that we have before, it is coming back after years

Clinical-stage biotechnology company pioneering
the development of lentivirus-based first-in-class
gene and cell therapies in cancer.

Genenta uses gene-based cytokine delivery
to activate the immune system within the tumor,
providing a controlled, targeted and enduring anti-tumor response.

https://www.genenta.com/

TEM-GBM_001